Improved Signs and Symptoms of Dry Eye Disease for Restasis ® Patients Following a Single Tearcare ® Treatment: Phase 2 of the SAHARA Study.

Brandon D AyresMarc R BloomensteinJennifer LohThomas ChesterBobby SaenzJulio EchegoyenShane R KannarrTomasita C RodriguezJaime E Dickerson

Published in: Clinical ophthalmology (Auckland, N.Z.) (2024)

SAHARA showed 6-month superiority of LHT to CsA in clinical signs and non-inferiority in symptom scores. This extension shows that patients treated with CsA for 6 months can achieve meaningful additional improvement in signs and symptoms lasting for as long as 6 months following a single LHT treatment without the need for topical prescription therapy.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
stem cells
peritoneal dialysis
replacement therapy
combination therapy
mesenchymal stem cells
patient reported